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Introduction: Metastatic spread to the brain is common in
patients with non–small cell lung cancer (NSCLC), but these
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March 2016 Afatinib in NSCLC and Brain Metastases 381activating mutation (LUX-Lung 6) investigated ﬁrst-line
afatinib versus platinum-based chemotherapy in
epidermal growth factor receptor gene (EGFR) mutation-
positive patients with NSCLC and included patients with
brain metastases; prespeciﬁed subgroup analyses are
assessed in this article.
Methods: For both LUX-Lung 3 and LUX-Lung 6, prespeciﬁed
subgroup analyses of progression-free survival (PFS), overall
survival, and objective response rate were undertaken in
patientswith asymptomatic brainmetastases at baseline (n¼
35 and n ¼ 46, respectively). Post hoc analyses of clinical
outcomes was undertaken in the combined data set (n¼ 81).
Results: In both studies, there was a trend toward
improved PFS with afatinib versus chemotherapy in pa-
tients with brain metastases (LUX-Lung 3: 11.1 versus 5.4
months, hazard ratio [HR] ¼ 0.54, p ¼ 0.1378; LUX-Lung 6:
8.2 versus 4.7 months, HR ¼ 0.47, p ¼ 0.1060). The
magnitude of PFS improvement with afatinib was similar to
that observed in patients without brain metastases. In
combined analysis, PFS was signiﬁcantly improved with
afatinib versus with chemotherapy in patients with brain
metastases (8.2 versus 5.4 months; HR, 0.50; p ¼ 0.0297).
Afatinib signiﬁcantly improved the objective response rate
versus chemotherapy in patients with brain metastases.
Safety ﬁndings were consistent with previous reports.
Conclusions: These ﬁndings lend support to the clinical
activity of afatinib in EGFR mutation–positive patients with
NSCLC and asymptomatic brain metastases.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Metastatic spread to the brain is common in patients
with advanced non–small cell lung cancer (NSCLC),
occurring in more than 25% of patients at some point
during their disease course.1 These patients have a poor
prognosis with a median survival of only 1 month from
diagnosis if untreated, 2 months with glucocorticoid
therapy, and 2 to 5 months with whole brain radiation
therapy (WBRT).1–7 Emerging evidence suggests that
patients with epidermal growth factor receptor gene
(EGFR) mutation–positive NSCLC are particularly prone
to the development of brain metastases, with the fre-
quency of such lesions in this patient subgroup ranging
from 44% to 63%.8,9 In the era of EGFR tyrosine kinase
inhibitors (TKIs), it is of high clinical relevance to deter-
mine the efﬁcacy and safety of these agents in patientswith EGFR mutation–positive NSCLC who present with
brain metastases. As most prospective clinical trials of
systemic therapy have excluded such patients because of
their poor prognosis10; however, there is currently a
paucity of prospective data on EGFR TKIs in patients with
brain metastases. Some retrospective data and small
phase II studies have indicated that these agents display
intracranial activity11–15; however, the data vary widely
and have not yet been formally validated.
Afatinib is an orally available, irreversible ErbB family
blocker that, in contrast to the ﬁrst-generation EGFR
TKIs, selectively and irreversibly blocks signaling from all
homodimers and heterodimers formed by the EGFR, erb-
b2 receptor tyrosine kinase 2 (HER2/ERBB2), HER3/
ERBB3, and HER4/ERBB4 receptors.16,17 In two large
phase III studies (LUX-Lung 3, which was conducted
globally, and LUX-Lung 6, which was conducted in China,
the Republic of Korea, and Thailand), afatinib demon-
strated signiﬁcantly improved progression-free survival
(PFS) rates, objective response rates (ORRs), and patient-
reported outcomes compared with platinum-based
chemotherapy (pemetrexed/cisplatin in LUX-Lung 3
and gemcitabine/cisplatin in LUX-Lung 6) as ﬁrst-line
treatment of patients with EGFR-mutated, advanced
NSCLC.18–20 Moreover, both studies showed afatinib to be
the only TKI to confer improved overall survival (OS)
versus standard-of-care platinum doublet chemotherapy
in patients harboring EGFR Del19 mutations, the most
common EGFR aberration in patients with NSCLC.21
Earlier studies of afatinib suggest that it is effective in
patients with NSCLC and brain metastases. Subgroup
analysis of LUX-Lung 2, a phase II trial of afatinib in pa-
tients with NSCLC and activating EGFR mutations,
showed that response rates were similar in patients with
or without brain metastases (65% and 60%, respec-
tively).22 Furthermore, in a recent compassionate use
program, 35% of patients with brain metastases and a
documented EGFRmutation had an intracranial response
when treated with afatinib.4 These data substantiate
preclinical and clinical observations that afatinib can
penetrate the blood-brain barrier at concentrations suf-
ﬁcient to elicit antitumor activity.4,23
Together, the phase III LUX-Lung 3 and LUX-Lung 6
trials represent the largest prospective data set on EGFR
mutation–positive patients with NSCLC treated with a
TKI. Owing to their nearly identical design, combined
analysis of the trials is feasible and facilitates robust
subanalyses in clinically relevant patient subgroups.
Both trials permitted the enrollment of patients with
clinically asymptomatic and controlled brain metastases.
In this study, we performed subgroup analyses of the
efﬁcacy of ﬁrst-line treatment with afatinib or platinum-
based chemotherapy in these patients. Analysis was
undertaken in both the individual trials and in a
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EGFR mutations represent a heterogeneous population
with variable responses to treatment,24 efﬁcacy analyses
focused on patients with common sensitizing EGFR mu-
tations. Given the observation that afatinib confers an OS
beneﬁt in patients with Del19,21 we also undertook an
analysis in patients with Del19 and L858R mutations
separately.Materials and Methods
Detailed study designs, patient inclusion and
exclusion criteria, and methods of the primary analyses
of LUX-Lung 3 and LUX-Lung 6 have been pub-
lished18,19 and are outlined only brieﬂy in the following
sections.Study Design and Patients
LUX-Lung 3 and LUX-Lung 6 were randomized, open-
label, phase III studies. Eligible patients had previously
untreated stage IIIB/IV lung adenocarcinoma harboring
EGFR mutations centrally conﬁrmed on the basis of
analysis of biopsy tissue with a validated test kit (Ther-
ascreen EGFR 29, Qiagen, Manchester, United Kingdom).
Patients were required to have an Eastern Cooperative
Oncology Group performance status of 0 or 1 and
measurable disease according to the Response Evaluation
Criteria in Solid Tumors (RECIST), version 1.1. Patients
with clinically asymptomatic and controlled brain me-
tastases (deﬁned as stable for at least 4 weeks and/or
asymptomatic and/or not requiring treatment with an-
ticonvulsants or steroids and/or no leptomeningeal dis-
ease) were included in both studies.
Each study was conducted in accordance with
the Declaration of Helsinki and International Confer-
ence on Harmonization Guidelines on Good Clinical
Practice, and the protocols were approved by local
ethics committees at each participating center. All
patients provided written informed consent for trial
participation.Study Treatment
Eligible patients were randomized 2:1 to receive
afatinib, 40 mg orally once daily, or up to 6 cycles of
intravenous platinum-based chemotherapy (LUX-Lung 3:
cisplatin, 75 mg/m2, and pemetrexed, 500 mg/m2, once
every 21 days; LUX-Lung 6: gemcitabine, 1000 mg/m2
on days 1 and 8, plus cisplatin, 75 mg/m2 on day 1 of
a 21-day cycle). Randomization was stratiﬁed by EGFR
mutation type (Del19, L858R, or other) and race (Asian
or non-Asian in LUX-Lung 3 only). Several prespeciﬁed
subgroup analyses, including presence of brain metas-
tases (yes/no), were deﬁned.Treatment with afatinib continued until investigator-
assessed disease progression or intolerable adverse
events (AEs). A well-deﬁned dose optimization protocol
for afatinib was utilized by investigators to maximize
efﬁcacy while managing tolerability. All patients had to
be initiated at the protocol-deﬁned and approved start-
ing dose of 40 mg.25,26 Dose escalation to 50 mg after the
ﬁrst 21-day cycle was allowed if a patient did not
experience treatment-related AEs with a grade higher
than 1. If a patient experienced any treatment-related
grade 3 or higher AE or selected prolonged grade 2
AEs, the dose of afatinib was reduced in 10-mg decre-
ments to a minimum of 20 mg. Afatinib was discontinued
if a patient experienced intolerable AEs at the dose of 20
mg. Dose reductions for patients receiving chemotherapy
were in accordance with guidance provided in the
summary of product characteristics and institutional
guidelines.
End Points and Assessments
For both LUX-Lung 3 and LUX-Lung 6, the primary
efﬁcacy end point was PFS, as assessed by independent
review. Key secondary end points in both studies were
OS, ORR (complete response and partial response), and
disease control (complete response/partial response or
stable disease). Other secondary end points included
patient-reported outcomes and safety.
In both studies, tumor assessmentswere performedby
computed tomography or magnetic resonance imaging
every 6 weeks for the ﬁrst 48 weeks, and then every 12
weeks until disease progression or start of new anticancer
therapy. Scans were subjected to independent central
radiologic review. Tumor response was determined ac-
cording to assessment of target lesions, nontarget lesions,
and the occurrence of new lesions, as per RECIST, version
1.1.27 Evaluation of intracranial lesions was performed as
part of standard RECIST imaging, but intracranial
response was not assessed as a separate end point. Safety
of study treatments was assessed according to the inci-
dence and intensity of AEs graded using the National
Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0, and changes in laboratory
parameters.
Statistical Analysis
Each study was powered (90%) at a two-sided 5%
signiﬁcance level to detect an improvement in median
PFS from 7 months for chemotherapy to 11 months for
afatinib. A minimum of 217 progression or death events
were required with estimated sample sizes of at least
330 patients for each study. The primary analysis of PFS
was performed approximately 30 months after study
initiation, when an initial analysis of OS was also
Figure 1. Patient disposition.
March 2016 Afatinib in NSCLC and Brain Metastases 383performed.18,19 A subsequent analysis of OS was planned
after approximately 209 deaths in LUX-Lung 3 and 237
deaths in LUX-Lung 6, when it was estimated that the
data would be mature.21 The data presented herein are
from the time point of the mature OS analysis.
Analysis of study end points was undertaken in
patients with common EGFR mutations. Data from
LUX-Lung 3 and LUX-Lung 6 were assessed indepen-
dently. Also, because the number of patients with
brain metastases in each study was relatively small, a
post hoc exploratory analysis of combined individual
patient data from LUX-Lung 3 and LUX-Lung 6 was
performed. Heterogeneity was evaluated by testing the
study-by-treatment interaction for this subgroup of
patients.
The main comparisons of PFS and OS between
treatment arms were performed using a log-rank test;
combined analyses were stratiﬁed by study (LUX-Lung 3
or LUX-Lung 6). Cox proportional hazard models were
used to derive hazard ratios (HRs) and corresponding
95% conﬁdence intervals (CIs) for the comparison be-
tween the two treatment arms. Kaplan-Meier estimates
were used to construct survival curves and calculate
median PFS and OS values. Logistic regression models
were used to compare ORRs and rates of disease control
between treatment groups.Results
Patients
A total of 42 of 345 randomized patients (12.2%) in
LUX-Lung 3 and 49 of 364 randomized patients (13.5%)
in LUX-Lung 6 had brain metastases present at baseline(Fig. 1). Most of these patients (35 [83.3%] and 46
[93.9%] in LUX-Lung 3 and LUX-Lung 6, respectively)
harbored common (Del19 and L858R) EGFR mutations.
In both studies, baseline characteristics were generally
well balanced between patients who did or did not have
brain metastases and across treatment groups (Table 1).
In patients with brain metastases, the proportion who
received prior WBRT was similar across trials and
treatment groups. In LUX-Lung 3, the frequency of prior
WBRT was 35.0% in the afatinib group and 33.3% in the
cisplatin-pemetrexed group. In LUX-Lung 6, 21.4% and
33.3% of patients in the afatinib and cisplatin-
gemcitabine groups received prior WBRT for brain
lesions.
In addition to the 81 patients described herein, a
further 10 patients with brain metastases (seven in LUX-
Lung 3 and three in LUX-Lung 6) (see Fig. 1) were found
to have uncommon EGFR mutations. Nine of these pa-
tients were treated with afatinib.Progression-Free Survival
In both studies, PFS was longer with afatinib than
with chemotherapy in patients with brain metastases
and common EGFR mutations but did not achieve sta-
tistical signiﬁcance, most likely because of small sample
size. In LUX-Lung 3, median PFS was 11.1 months with
afatinib and 5.4 months with cisplatin-pemetrexed
(HR ¼ 0.54, 95% CI: 0.23–1.25, p ¼ 0.1378) (Fig. 2A).
The magnitude of PFS improvement with afatinib over
chemotherapy was similar to that observed in patients
without brain metastases (13.8 versus 8.1 months, HR ¼
0.48, 95% CI: 0.34–0.69, p < 0.0001) (see Fig. 2A). In
Table 1. Baseline Demographics and Clinical Characteristics of Patients with Common EGFR Mutations and with or without Brain Metastases (Randomized Set)
Characteristic
LUX-Lung 3 LUX-Lung 6
Afatinib Cisplatin-Pemetrexed Afatinib Cisplatin-Gemcitabine
Without BM
(n ¼ 166)
With BM
(n ¼ 20)
Without BM
(n ¼ 82)
With BM
(n ¼ 15)
Without BM
(n ¼ 185)
With BM
(n ¼ 28)
Without BM
(n ¼ 86)
With BM
(n ¼ 18)
Median age (range), y 63.0 (3586) 60.5 (3771) 61.0 (3783) 63.0 (3174) 58.0 (2977) 53.5 (3078) 58.0 (2776) 55.0 (3570)
Gender, n (%)
Male 56 (33.7) 6 (30.0) 27 (32.9) 3 (20.0) 66 (35.7) 9 (32.1) 27 (31.4) 6 (33.3)
Female 110 (66.3) 14 (70.0) 55 (67.1) 12 (80.0) 119 (64.3) 19 (67.9) 59 (68.6) 12 (66.7)
Race, n (%)
White 47 (28.3) 3 (15.0) 24 (29.3) 3 (20.0) 0 0 0 0
Asian 117 (70.5) 17 (85.0) 56 (68.3) 12 (80.0) 185 (100.0) 28 (100.0) 86 (100.0) 18 (100.0)
Other 2 (1.2) 0 2 (2.4) 0 0 0 0 0
Smoking status, n (%)
Never smoked 113 (68.1) 14 (70.0) 54 (65.9) 13 (86.7) 139 (75.1) 23 (82.1) 72 (83.7) 13 (72.2)
Ex-smoker 50 (30.1) 6 (30.0) 27 (32.9) 1 (6.7) 32 (17.3) 3 (10.7) 8 (9.3) 2 (11.1)
Current smoker 3 (1.8) 0 1 (1.2) 1 (6.7) 14 (7.6) 2 (7.1) 6 (7.0) 3 (16.7)
ECOG PS, n (%)
0 72 (43.4) 4 (20.0) 29 (35.4) 7 (46.7) 39 (21.1) 4 (14.3) 30 (34.9) 5 (27.8)
1 94 (56.6) 16 (80.0) 52 (63.4) 8 (53.3) 146 (78.9) 24 (85.7) 56 (65.1) 13 (72.2)
2 0 0 1 (1.2) 0 0 0 0 0
Adenocarcinoma stage, n (%)
IIIB 18 (10.8) 0 13 (15.9) 0 16 (8.6) 0 6 (7.0) 0
IV 148 (89.2) 20 (100.0) 69 (84.1) 15 (100.0) 169 (91.4) 28 (100.0) 80 (93.0) 18 (100.0)
EGFR mutation, n (%)
L858R alone 77 (46.4) 9 (45.0) 36 (43.9) 7 (46.7) 77 (41.6) 10 (35.7) 34 (39.5) 11 (61.1)
L858R þ Del19a 0 0 0 0 3 (1.6) 1 (3.6) 0 0
Del19 alone 89 (53.6) 11 (55.0) 46 (56.1) 8 (53.3) 105 (56.8) 17 (60.7) 52 (60.5) 7 (38.9)
Prior whole brain radiotherapy, n (%)
Yes 2 (1.2) 7 (35.0) 0 5 (33.3) 0 6 (21.4) 0 6 (33.3)
No 164 (98.8) 13 (65.0) 82 (100.0) 10 (66.7) 185 (100.0) 22 (78.6) 86 (100.0) 12 (66.7)
aIncluded in the L858R group for analysis.
BM, brain metastases; ECOG, European Cooperative Oncology Group; EGFR, epidermal growth factor receptor gene; LUX-Lung 3, phase III study of Afatinib or Cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations; LUX-Lung 6, a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as ﬁrst-line treatment for
patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation; PS, performance status.
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Figure 2. Progression-free survival in patients with non–small cell lung cancer and common epidermal growth factor receptor
gene (EGFR) mutations (Del19/L858R), with and without brain metastases treated with either afatinib or platinum-doublet
chemotherapy in the studies Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung
Adenocarcinoma With EGFR Mutations (A) and LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus
Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR
Activating Mutation (B).
March 2016 Afatinib in NSCLC and Brain Metastases 385LUX-Lung 6, median PFS of patients with brain metas-
tases treated with afatinib was 8.2 months versus 4.7
months in patients receiving cisplatin-gemcitabine
(HR ¼ 0.47, 95% CI: 0.18–1.21, p ¼ 0.1060) (Fig. 2B).
In patients without brain metastases, median PFS was
11.1 with afatinib and 5.6 months with chemotherapy
(HR ¼ 0.22, 95% CI: 0.15–0.33, p < 0.0001) (see Fig. 2B).
To increase the sample size of patients with brain
metastases, we undertook a combined analysis of LUX-
Lung 3 and LUX-Lung 6. Given the caveat that the
two trials used different chemotherapy regimens as
comparators, this analysis was exploratory only. Never-
theless, compared with chemotherapy, afatinib signiﬁ-
cantly improved PFS in patients with NSCLC plus brain
metastases and common EGFR mutations (median PFS
8.2 versus 5.4 months, HR ¼ 0.50, 95% CI: 0.27–0.95,p ¼ 0.0297) (Fig. 3). Interestingly, the PFS beneﬁt
conferred by afatinib in patients with brain metastases
was higher in those who received prior WBRT (n ¼ 24,
13.8 versus 4.7 months, HR ¼ 0.37, 95% CI: 0.12–1.17,
p¼ 0.0767) than in those who did not (n¼ 57, 6.9 versus
5.4 months, HR ¼ 0.62, 95% CI: 0.28–1.36, p ¼ 0.2222).
Further analysis of a combined patient data set was
undertaken in patients with brain metastases and spe-
ciﬁc EGFR mutations (see Fig. Supplemental Digital
Content 1, which demonstrates PFS and best response
with respect to mutation type in individual patients). In
patients with a Del19 mutation, afatinib signiﬁcantly
improved PFS versus chemotherapy (n ¼ 43, 9.5 versus
4.7 months, HR ¼ 0.24, 95% CI: 0.09–0.62, p ¼ 0.0012)
(see Fig. Supplemental Digital Content 2, which shows
Kaplan-Meier PFS curves according to mutation type). In
Figure 3. Progression-free survival and overall survival in patients with non–small cell lung cancer and baseline brain me-
tastases and common epidermal growth factor receptor gene (EGFR) mutations on the basis of an exploratory combined
analysis of the studies Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocar-
cinoma With EGFR Mutations and LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy
as First-line Treatment for Patients With Stage IIIB or IVAdenocarcinoma of the Lung Harbouring an EGFR Activating Mutation.
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afatinib and chemotherapy in patients with the L858R
mutation (n ¼ 38, 6.9 versus 9.7 months, HR ¼ 0.90,
95% CI: 0.36–2.27, p ¼ 0.8289). In the additional nine
patients with uncommon EGFR mutations and brain
metastases who were treated with afatinib, PFS ranged
from 1.1 to 22 months (see Fig. Supplemental Digital
Content 3, which shows PFS and best response in indi-
vidual patients with uncommon EGFR mutations).
In patients with baseline brain metastases and com-
mon EGFR mutations treated with afatinib, rates of
central nervous system (CNS) progression were similar
in patients treated with afatinib (nine [45.0%] in LUX-
Lung 3 and six [21.4%] in LUX-Lung 6) or chemo-
therapy (ﬁve [33.3%] in LUX-Lung 3 and ﬁve [27.8%] in
LUX-Lung 6). The rates of CNS progression in patients
without baseline brain metastases were also similar in
patients treated with afatinib (12 [7.2%] in LUX-Lung 3
and 10 [5.4%] in LUX-Lung 6) or chemotherapy (three
[3.7%] in LUX-Lung 3 and four [4.7%] in LUX-Lung 6).
Interestingly, the median time to CNS progression was
longer with afatinib versus with chemotherapy (LUX-
Lung 3: 15.2 months [95% CI: 7.7–29.0] and 5.7 months
[95% CI: 2.6–8.2]; LUX-Lung 6: 15.2 months [95% CI:
3.8–23.7] and 7.3 months [95% CI: 3.7–10.9] with afa-
tinib and chemotherapy, respectively). However, the
patient numbers in this analysis were small and preclude
deﬁnitive conclusions.OS
There was no signiﬁcant difference in OS in patients
with brain metastases who were treated with afatinib orchemotherapy (LUX-Lung 3: median OS 19.8 versus 33.2
months, HR ¼ 1.15, 95% CI: 0.49–2.67, p ¼ 0.7517; LUX-
Lung 6: 22.4 versus 24.7 months, HR ¼ 1.13, 95% CI:
0.56–2.26, p ¼ 0.7315; and combined data set: 22.4
versus 25.0 months, HR ¼ 1.14, 95% CI: 0.66–1.94, p ¼
0.6412) (Figs. 3 and 4).
OS was also assessed according to type of EGFR
mutation. There was no signiﬁcant difference in OS be-
tween afatinib and chemotherapy in patients with brain
metastases and a Del19 mutation (22.4 versus 20.6
months; HR ¼ 0.78, 95% CI: 0.37–1.66, p ¼ 0.5229) nor
in patients with brain metastases and an L858R muta-
tion (22.6 versus 26.2 months, HR ¼ 1.53, 95% CI: 0.69–
3.41, p ¼ 0.2897) (see Fig. Supplemental Digital Content
2, which shows Kaplan-Meier OS curves according to
mutation type).Tumor Response Rate
In both LUX-Lung 3 and 6, ORR was signiﬁcantly
greater with afatinib than with chemotherapy in patients
with brain metastases and common EGFR mutations
(Table 2). Across both studies, the ORR in patients with
brain metastases who were treated with afatinib was
23 of 28 (82.1%) and 12 of 20 (60.0%) in those with
Del19 or L858R mutations, respectively (see Fig.
Supplemental Digital Content 1, which demonstrates
PFS and best response with respect to mutation type in
individual patients). Disease control rates were also
higher with afatinib than with chemotherapy but did not
reach statistical signiﬁcance. Additionally, in patients
with uncommon EGFR mutations and brain metastases,
ORR was observed in three of nine patients (33.3%)
Figure 4. Overall survival in patients with non–small cell lung cancer and common epidermal growth factor receptor gene
(EGFR) mutations (Del19/L858R), with and without brain metastases treated with either afatinib or platinum-doublet
chemotherapy in the studies Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung
Adenocarcinoma With EGFR Mutations (A) and LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus
Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR
Activating Mutation (B).
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Content 3, which shows PFS and best response in indi-
vidual patients with uncommon EGFR mutations).Safety and Tolerability
In both studies, the AE proﬁle of patients with brain
metastases was similar to that of those without brain
metastases for both treatment groups, with no unex-
pected safety ﬁndings (see Supplemental Digital Content
4, which shows treatment-related grade 3 AEs). The
incidence of grade 3 or 4 AEs in patients without brain
metastases treatedwith afatinibwas 49.5% in LUX-Lung 3
versus 36.4% in LUX-Lung 6. In patients with brainmetastases, 46.2%and33%of patients experienced grade
3 or 4 AEs in LUX-Lung 3 and LUX-Lung 6, respectively.
Discussion
In this study, we utilized the phase III LUX-Lung 3 and
LUX-Lung 6 data sets to assess the activity of afatinib in
the prespeciﬁed subset of patients with EGFR mutation–
positive NSCLC who presented with baseline brain me-
tastases. Of the 91 individuals identiﬁed as belonging
to this subset, 81 harbored common EGFR mutations;
they constituted the largest prospective cohort of such
patients to be analyzed for response to a TKI. Several
observations in this analysis suggest that patients with
Table 2. Tumor Response Rates in Patients with and without Brain Metastases and Common EGFR Mutations in LUX-Lung 3
and 6
Outcome With Brain Metastases No Brain Metastases
LUX-Lung 3
Afatinib
n ¼ 20
Cisplatin-pemetrexed
n ¼ 15 p Value
Afatinib
n ¼ 166
Cisplatin-pemetrexed
n ¼ 82 p Value
ORR, n
(%, 95% CI)
14 (70.0, 45.7–88.1) 3 (20.0, 4.3–48.1) 0.0058 100 (60.2, 52.4–67.7) 19 (23.2, 14.6–33.8) <0.0001
DCR, n
(%, 95% CI)
19 (95.0, 75.1–99.9) 12 (80.0, 51.9–95.7) 0.1986 157 (94.6, 90.0–97.5) 65 (79.3, 68.9–87.4) 0.0005
LUX-Lung 6
Afatinib
n ¼ 28
Cisplatin-gemcitabine
n ¼ 18 p Value
Afatinib
n ¼ 185
Cisplatin-gemcitabine
n ¼ 86 p Value
ORR, n
(%, 95% CI)
21 (75.0, 55.1–89.3) 5 (27.8, 9.7–53.5) 0.0027 124 (67.0, 59.7–73.7) 19 (22.1, 13.9–32.3) <0.0001
DCR, n
(%, 95% CI)
25 (89.3, 71.8–97.7) 13 (72.2, 46.5–90.3) 0.1486 171 (92.4, 87.6–95.8) 66 (76.7, 66.4–85.2) 0.0005
EGFR, epidermal growth factor receptor gene; LUX-Lung 3, phase III study of Afatinib or Cisplatin plus Pemetrexed in patients with
metastatic lung adenocarcinoma with EGFR mutations; LUX-Lung 6, a randomized, open-label, phase III study of BIBW 2992 versus
chemotherapy as ﬁrst-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation;
ORR, objective response rate; CI, conﬁdence interval; DCR, disease control rate.
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from treatment with afatinib. First, in both studies, afa-
tinib conferred longer PFS versus chemotherapy in pa-
tients with brain metastases who harbored common
EGFR mutations. The outcomes were particularly prom-
ising in patients with a Del19 mutation, a subgroup for
whom afatinib is the only TKI to demonstrate superior OS
versus chemotherapy in this setting.21 Second, afatinib
conferred a signiﬁcantly higher ORR (extracranial) versus
chemotherapy in this subset of patients with baseline
brain metastases. Indeed, response rates were similar to
those observed in patients without baseline brain me-
tastases. ORR was signiﬁcantly greater with afatinib
versus chemotherapy in patients with brain metastases,
with similar ORRs observed between patients with or
without these lesions. Of note, the brain was not the site
of ﬁrst disease progression for most patients, suggesting
that afatinib and chemotherapy may confer disease con-
trol on CNS lesions. Finally, the AE proﬁle for afatinib in
patients with brain metastases was similar to that in
those without brain metastases, with no unexpected
safety-related ﬁndings.
In the present study, intracranial response rates were
not assessed. Therefore, no direct conclusions can be
made regarding afatinib’s ability to cross the blood-brain
barrier in concentrations sufﬁcient to elicit CNS re-
sponses; however, previous studies indicate that this
may be the case. In a recent report on a compassionate
use program, 100 patients with brain metastases and/or
leptomeningeal disease were treated with afatinib
following progression after chemotherapy and EGFR-TKI
treatment.4 The median time to treatment failure was
3.6 months, which did not differ from that in a matchedgroup of 100 patients without CNS metastases. There-
fore, it seems that afatinib may be able to attain clinical
activity in the brain. Interestingly, in our study, the
magnitude of PFS beneﬁt from afatinib favored those
patients who had received WBRT before study entry,
although statistical signiﬁcance was not reached. As
WBRT is reported to increase the permeability of the
blood-brain barrier,28 this observation might indirectly
point to a dose effect of afatinib in the brain. Case study
data with ﬁrst-generation EGFR inhibitors indicate
that the level of CNS penetration can be improved with
pulsatile high-dose administration regimens.29–33 It will
be interesting, therefore, to assess the efﬁcacy of pulsed-
dose afatinib in patients with brain metastases. Another
area that requires further study is the ability of afatinib
to control active brain metastases (an exclusion criterion
in both LUX-Lung 3 and LUX-Lung 6).
In addition to the current study with afatinib, several
retrospective or small phase II studies have shown that
geﬁtinib/afatinib can improve outcomes in patients with
EGFR-mutated NSCLC that has metastasized to the brain.
Response rates (per RECIST criteria, not intracranial
responses) between 58% and 83% have been reported,
and median PFS and OS were in the range of 7 to 15
months and 13 to 18 months, respectively.13–15 Given
the apparent efﬁcacy of these agents, it is interesting to
speculate how TKIs could potentially become incorpo-
rated into current standard treatment regimens for pa-
tients with brain metastases. It is possible, for example,
that in patients with asymptomatic brain metastases
treatment with a ﬁrst-line TKI could delay the require-
ment for WBRT, thereby delaying or preventing expo-
sure to the side effects of cranial irradiation. Indeed, in
March 2016 Afatinib in NSCLC and Brain Metastases 389some studies, tumor responses achieved by EGFR TKIs
have successfully delayed the requirement for
WBRT.12,13 In this study, however, disease control app-
eared to be better in patients who had previously
received WBRT, suggesting that sequential approaches
warrant careful investigation.
In summary, the ﬁndings of the current analysis lend
further support to the efﬁcacy of afatinib in asymptom-
atic brain metastases secondary to NSCLC harboring
common EGFR mutations, and they add valuable insights
into a clinically unmet need. Further studies exploring
the effects of afatinib in patients with NSCLC and EGFR
mutations and brain metastases are warranted.
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